The latest NICE guidelines recommend the use of SGLT2 inhibitors with metformin as dual therapy first line for patients with diabetes with established cardiovascular disease, and advise to consider their use in patients with high risk of cardiovascular disease [58]. Here, SLC5A2 is linked to cardiovascular disorder.